Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.31 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13443499 | 0.82 | L3MBTL1 (0.36) | KDM4EMEN1TSHRKMT2A | |
| SCHEMBL20833449 | 0.80 | KDM4E (0.39) | KDM4EMEN1TSHRKMT2AHPRT1 | |
| SCHEMBL20833441 | 0.80 | KDM4E (0.39) | KDM4EMEN1TSHRKMT2AHPRT1 | |
| SCHEMBL22759882 | 0.79 | CCNB2 (0.35) | CDK5CDK5R1CCNB2CDK1CCNB1 | |
| SCHEMBL25605598 | 0.79 | KDM4E (0.37) | KDM4ECDK5CDK5R1MEN1TSHR | |
| SCHEMBL22399679 | 0.79 | KDM4E (0.37) | KDM4ECDK5CDK5R1MEN1TSHR | |
| SCHEMBL22335430 | 0.74 | KDM4E (0.46) | KDM4EMEN1KMT2A | |
| SCHEMBL20833132 | 0.74 | KDM4E (0.48) | KDM4EMEN1KMT2A | |
| SCHEMBL24102841 | 0.73 | KDM4E (0.54) | KDM4EMEN1TSHRKMT2A | |
| SCHEMBL23898886 | 0.73 | KDM4E (0.54) | KDM4EMEN1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200385725-A1 | UNA AMIDITES AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385725-A1 | UNA AMIDITES AND USES THEREOF | NCL, PNP, NASP | KDM4E 4566/4885CDK5 2862/4885CDK5R1 2845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.